Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines
- Authors
- Heo, Jung Yeon; Seo, Yu Bin; Jeong, Hye Won; Choi, Min Joo; Min, Kyung Hoon; Choi, Won Suk; Lee, Jacob; Noh, Ji Yun; Cheong, Hee Jin; Kim, Woo Joo; Song, Joon Young
- Issue Date
- 17-11월-2020
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Community-acquired pneumonia; Epidemiology; Incidence; Mortality; Pneumococcus
- Citation
- VACCINE, v.38, no.49, pp.7747 - 7755
- Indexed
- SCIE
SCOPUS
- Journal Title
- VACCINE
- Volume
- 38
- Number
- 49
- Start Page
- 7747
- End Page
- 7755
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/138897
- DOI
- 10.1016/j.vaccine.2020.10.046
- ISSN
- 0264-410X
- Abstract
- Background: South Korea has been providing 10-valent pneumococcal conjugate vaccine/(PCV10)/13-valent pneumococcal conjugate vaccine (PCV13) to children and 23-valent pneumococcal polysaccharide vaccine (PPSV23) to older adults as part of a national immunization program. Methods: From September 2015 to August 2017, a prospective cohort study was conducted for adults aged >= 19 years with community-acquired pneumonia (CAP) at four university hospitals. All-cause and pneumococcal CAP incidence and mortality rates were evaluated on the basis of hospital catchment population. Serotype distribution of pneumococcal CAP was also evaluated. Results: Among 2669 patients with CAP, 252 cases (9.4%) were pneumococcal CAP cases. The annual incidences of all-cause and pneumococcal CAP were 194.3 cases and 18.3 cases respectively, per 100,000 persons. Serotyped Streptococcus pneumoniae was identified in 107 cases (42.5%) through culture or a serotype-specific urinary antigen detection assay. Pneumococcal CAP caused by the PCV13 and PPSV23 serotypes were 50 cases (46.7% of serotyped pneumococcal CAP and 19.8% of pneumococcal CAP), and 83 cases (77.6% of serotyped pneumococcal CAP and 32.9% of pneumococcal CAP), respectively. The most prevalent serotype was 3 (n = 21, 19.6% of serotyped pneumococcal CAP), followed by 19A (n = 10, 9.3% of serotyped pneumococcal CAP) and 11A (n = 10, 9.3% of serotyped pneumococcal CAP). Compared with non-pneumococcal CAP patients, pneumococcal CAP patients were more likely to have a higher CURB65 scores (P = 0.002). The overall 30-day mortality rate of pneumococcal CAP was higher than that of non-pneumococcal CAP (6.3% versus 5.6%; odds ratio [OR], 1.15; 95% confidence interval [CI], 0.67-1.96), but this trend was reversed in patients aged 65-74 years (4.2% versus 8.6%; OR, 0.47; 95% CI, 0.14-1.54). Conclusions: The disease burden of PCV13-serotype pneumococcal CAP remains significantly high in Korean adults, particularly among elderly people, even after a high uptake of pediatric PCVs. (C) 2020 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
- Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.